Our Team: Driven & Diverse

Our experienced leadership and clinical development team in Cambridge has deep relationships with the world’s top cancer centers and extensive experience in company-building and drug development. Working towards a shared vision to provide first-in-class, meaningful therapies to cancer patients, we have partnered with skilled protein engineers, immunologists and CMC experts who have experience building highly complex molecules and a track record of developing FDA-approved drugs.


Claire Mazumdar, Ph.D., MBA

Chief Executive Officer

Ryan Cohlhepp, Pharm.D.

President & Chief Operating Officer

Ivan Hyep, MBA

Chief Financial Officer

Dr. David Raben, M.D.

Chief Medical Officer

Lara Meisner, J.D.

Chief Legal Officer

Rachel Salazar, D.H.Sc.

SVP, R&D Strategy & Operations

Sathish Hasige, Ph.D.

SVP, Head of Technical Operations & Supply Chain
David Bohr

David Bohr, MBA, MS

VP, Clinical Operations

Angela Windt, Pharm.D.

VP, Head of Regulatory Affairs

Gary Bostanxhi, MBA

VP, Finance

John Maraganore, Ph.D.

Executive Advisor

Board of Directors

Nils Lonberg, Ph.D.

Chairman of the Board
Canaan Partners

Claire Mazumdar, Ph.D., MBA

Board Director
Bicara Therapeutics

Carolyn Ng, Ph.D.

Board Director
TPG Life Sciences Innovations

Vijay Kuchroo, D.V.M., Ph.D.

Board Director
Harvard Medical School

Kiran Mazumdar-Shaw

Board Director
Biocon, Ltd.

Heath Lukatch, Ph.D.

Board Director
Red Tree Venture Capital
Jake Simson

Jake Simson, Ph.D.

Board Director
RA Capital
Ketan Patel

Ketan Patel, M.D., MBA

Board Director
F-Prime Capital

Kate Haviland, MBA

Board Director
Blueprint Medicines

Scott Robertson, MBA

Board Director
Star Therapeutics

Board Observers


  • RA Capital

  • FPrime

  • Omega Funds

  • JanusHenderson

  • Bioqube

  • Acorn Bioventures

  • Eight Roads

  • Premji

  • Biocon